Dr. Jeffrey Nau, CEO of Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company discusses the company’s lead candidate, OC-01, a nasal spray being developed to treat the signs and symptoms of dry eye disease (DED). Current treatment options are limited to eye drops, which can be difficult and uncomfortable to self-administer. The FDA accepted their New Drug Application for OC-01, which was supported by safety and efficacy results from clinical trials in over 1,000 patients with mild, moderate, or severe symptoms of DED. The U.S. launch of OC-01 nasal spray is planned for the fourth quarter of 2021, if approved by the FDA.
Jeffrey Nau, PhD, MMS, President and Chief Executive Officer. Jeff has built his career on developing novel, innovative therapies for diseases of the eye, with over 15 years of experience working with biotechnology, pharmaceutical, and medical device companies. Most recently, he was VP, Clinical and Medical Affairs, at Ophthotech. Prior to that, Jeff was a Medical Science Director at Genentech working on the development of Lucentis®, a transformative drug for retinal diseases. Jeff has helped raise more than $250 million in equity for innovative startups such as Genaera Corporation, Acuity Pharmaceuticals, and NeoVista, Inc. He holds numerous patents and peer-reviewed publications. Jeff has a Ph.D. in Public Health and Epidemiology from Walden University, a M.S. in Medical Science from MCP Hahnemann School of Medicine, and a B.S. in Biology from Stony Brook University.